Jonathan Wolleben
Stock Analyst at JMP Securities
(2.03)
# 2,791
Out of 4,827 analysts
197
Total ratings
100%
Success rate
0.49%
Average return
Main Sectors:
Stocks Rated by Jonathan Wolleben
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Reiterates: Market Outperform | $443 | $303.99 | +45.73% | 12 | Apr 24, 2025 | |
| MBX MBX Biosciences | Initiates: Market Outperform | $38 | $11.68 | +225.47% | 1 | Apr 10, 2025 | |
| ALT Altimmune | Reiterates: Market Outperform | $25 | $5.74 | +335.54% | 12 | Apr 2, 2025 | |
| CLSD Clearside Biomedical | Reiterates: Market Outperform | $5 | $0.86 | +483.50% | 10 | Mar 28, 2025 | |
| KALV KalVista Pharmaceuticals | Reiterates: Market Outperform | $19 | $12.27 | +54.85% | 3 | Mar 26, 2025 | |
| AURA Aura Biosciences | Maintains: Market Outperform | $21 → $19 | $5.74 | +231.01% | 7 | Mar 26, 2025 | |
| SKYE Skye Bioscience | Reiterates: Market Outperform | $15 | $1.77 | +749.86% | 2 | Mar 21, 2025 | |
| PTGX Protagonist Therapeutics | Reiterates: Market Outperform | $61 | $43.77 | +39.38% | 11 | Mar 10, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Market Outperform | $22 → $19 | $7.26 | +161.71% | 17 | Mar 4, 2025 | |
| DBVT DBV Technologies | Reiterates: Market Outperform | $10 | $9.67 | +3.47% | 13 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $55 | $17.12 | +221.26% | 11 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $18 | $10.07 | +78.84% | 7 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $26 | $4.46 | +482.96% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $91 → $87 | $26.67 | +226.21% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $92 → $91 | $32.64 | +178.80% | 14 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $74 | $46.34 | +59.69% | 9 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $75 | $60.43 | +24.11% | 2 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $3.06 | +194.12% | 8 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $55 → $50 | $39.49 | +26.61% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $90 | $76.48 | +17.68% | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $126.97 | - | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $1.54 | +419.48% | 7 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Accumulate | $420 → $485 | $660.00 | -26.52% | 1 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $3 | $0.33 | +814.63% | 6 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $48 → $32 | $3.35 | +855.22% | 8 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $25 | $2.20 | +1,038.95% | 11 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $0.30 | +2,567.56% | 11 | Apr 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $24 | $27.89 | -13.95% | 1 | May 12, 2023 |
Madrigal Pharmaceuticals
Apr 24, 2025
Reiterates: Market Outperform
Price Target: $443
Current: $303.99
Upside: +45.73%
MBX Biosciences
Apr 10, 2025
Initiates: Market Outperform
Price Target: $38
Current: $11.68
Upside: +225.47%
Altimmune
Apr 2, 2025
Reiterates: Market Outperform
Price Target: $25
Current: $5.74
Upside: +335.54%
Clearside Biomedical
Mar 28, 2025
Reiterates: Market Outperform
Price Target: $5
Current: $0.86
Upside: +483.50%
KalVista Pharmaceuticals
Mar 26, 2025
Reiterates: Market Outperform
Price Target: $19
Current: $12.27
Upside: +54.85%
Aura Biosciences
Mar 26, 2025
Maintains: Market Outperform
Price Target: $21 → $19
Current: $5.74
Upside: +231.01%
Skye Bioscience
Mar 21, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $1.77
Upside: +749.86%
Protagonist Therapeutics
Mar 10, 2025
Reiterates: Market Outperform
Price Target: $61
Current: $43.77
Upside: +39.38%
Ocular Therapeutix
Mar 4, 2025
Maintains: Market Outperform
Price Target: $22 → $19
Current: $7.26
Upside: +161.71%
DBV Technologies
Mar 4, 2025
Reiterates: Market Outperform
Price Target: $10
Current: $9.67
Upside: +3.47%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $55
Current: $17.12
Upside: +221.26%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $10.07
Upside: +78.84%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $26
Current: $4.46
Upside: +482.96%
Feb 28, 2025
Maintains: Market Outperform
Price Target: $91 → $87
Current: $26.67
Upside: +226.21%
Feb 28, 2025
Maintains: Market Outperform
Price Target: $92 → $91
Current: $32.64
Upside: +178.80%
Feb 24, 2025
Reiterates: Market Outperform
Price Target: $74
Current: $46.34
Upside: +59.69%
Dec 23, 2024
Reiterates: Market Outperform
Price Target: $75
Current: $60.43
Upside: +24.11%
Dec 19, 2024
Reiterates: Market Outperform
Price Target: $9
Current: $3.06
Upside: +194.12%
Dec 18, 2024
Maintains: Market Outperform
Price Target: $55 → $50
Current: $39.49
Upside: +26.61%
Dec 16, 2024
Reiterates: Market Outperform
Price Target: $90
Current: $76.48
Upside: +17.68%
Dec 16, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $126.97
Upside: -
Dec 12, 2024
Reiterates: Market Outperform
Price Target: $8
Current: $1.54
Upside: +419.48%
Nov 13, 2024
Downgrades: Accumulate
Price Target: $420 → $485
Current: $660.00
Upside: -26.52%
Sep 26, 2024
Reiterates: Market Outperform
Price Target: $3
Current: $0.33
Upside: +814.63%
Aug 15, 2024
Maintains: Market Outperform
Price Target: $48 → $32
Current: $3.35
Upside: +855.22%
May 31, 2024
Reiterates: Market Outperform
Price Target: $25
Current: $2.20
Upside: +1,038.95%
Apr 19, 2024
Reiterates: Market Outperform
Price Target: $8
Current: $0.30
Upside: +2,567.56%
May 12, 2023
Maintains: Outperform
Price Target: $25 → $24
Current: $27.89
Upside: -13.95%